URO17® Bladder Cancer Test
Bladder Cancer Detection and Monitoring
Pivotal Clinical TrialActive
Key Facts
Indication
Bladder Cancer Detection and Monitoring
Phase
Pivotal Clinical Trial
Status
Active
Company
About KDx Diagnostics
KDx Diagnostics is a private, commercial-stage diagnostics company specializing in bladder cancer detection with its URO17® test. The test, based on the novel Keratin 17 (K17) biomarker, has demonstrated high sensitivity and specificity in clinical studies and has received FDA Breakthrough Device Designation. The company is currently conducting a clinical trial for FDA approval while generating early revenue through LDT and international kit sales.
View full company profile